Product Description
Mechanisms of Action: TK Inhibitor,VEGF Inhibitor,PGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Adenocarcinoma|Gastrointestinal Cancer|Intestinal Diseases
Phase 2: Non-Small-Cell Lung Cancer|Macular Degeneration|Endometriosis|Hepatocellular Carcinoma|Colorectal Cancer|Breast Cancer|Renal Cell Carcinoma|Adenocarcinoma
Phase 1: Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ELTA | P2 |
Withdrawn |
Endometriosis |
2021-10-10 |
48% |
| M10-966 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2012-08-01 |
|
| JapicCTI-101322 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2012-08-01 |
|
| LiGHT | P3 |
Terminated |
Hepatocellular Carcinoma |
2012-07-24 |